Additional studies are still needed to elucidate the CIL-102 effects on the HAT and HDAC between different molecular cellular signaling pathways and epigenetic machinery as well as to determine in vivo CRC cells’ xenograft and CIL-102 dose treatment. This evidence concerns the gene HDAC9 and colorectal carcinoma.